A statement released earlier today by Jefferies & Co about Catalent (NYSE:CTLT) bumps the target price to $28.00
- Updated: September 29, 2016
Jefferies & Co bumped up the target of Catalent (NYSE:CTLT) to $28.00 indicating a possible upside of 0.09%.
Yesterday Catalent (NYSE:CTLT) traded -2.28% lower at $25.72. The company’s 50-day moving average is $25.20 and its 200-day moving average is $25.67. The last stock close price is up 0.16% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 777,402 shares of the stock were exchanged, down from an average trading volume of 1,206,980
See Chart Below
Catalent has a 52 week low of $18.92 and a 52 week high of $32.24 with a P/E ratio of 28.89 The company’s market cap is currently $0.
In addition to Jefferies & Co reporting its target price, a total of 6 firms have reported on the stock. The consensus target price is $27.92 with 0 firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
About Catalent (NYSE:CTLT)
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.